Bridget Keenan

MD PhD

Medical oncologist
Cancer researcher and outdoor enthusiast

About me

Pronouns: She | Her | Hers

Telehealth (video visits)
Insurance plan info

Dr. Bridget Keenan is an oncologist and physician-scientist, a doctor particularly focused on research. She cares for patients with solid organ tumors who are seeking or enrolled in immunotherapy clinical trials (studies of promising new treatments). She has a special interest in digestive system cancers.

Keenan's research investigates various immunotherapy approaches to fighting cancer, including checkpoint inhibitors (drugs that prevent an immune system response that may otherwise allow cancer cells to evade destruction), cellular therapies, bispecific antibodies (parts of lab-produced antibodies that bind to T cells and tumors so that cancer cells are directly targeted) and other new treatments.

Keenan earned her medical degree and a doctorate in immunology at the Johns Hopkins University School of Medicine. At UCSF, she completed a residency in internal medicine and a fellowship in hematology and oncology.

  • Education

    Johns Hopkins School of Medicine, MD, 2015

    John Hopkins School of Medicine, PhD, Immunology, 2015

  • Residencies

    UCSF, Internal Medicine, 2017

  • Fellowships

    UCSF, Hematology-Oncology, 2021

  • Academic Title

    Assistant Professor

I help patients with cancer learn whether an immunotherapy clinical trial is right for them and research better treatments using the immune system.

Where I see patients (1)

    Selected research

    See all research
    Decorative Caduceus

    A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

    Determine if treatment with AZD5851 is safe and tolerable through assessment of DLTs, AEs, SAEs and changes from baseline in vital signs, ECGs, and laboratory parameters

    Recruiting

    Decorative Caduceus

    A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can...

    Recruiting

    Decorative Caduceus

    First-in-Human Study of TAK-280 in Participants With Solid Tumors

    DLT evaluation period is defined as the time between the initial dose of TAK-280 and Cycle 1 Day 28.

    Recruiting

    Decorative Caduceus

    A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

    Evaluate the safety and tolerability of ATG-031

    Recruiting

    Decorative Caduceus

    A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

    Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of consent until the end of the study visit or at the end of treatment visit.

    Recruiting

    Decorative Caduceus

    A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin...

    To evaluate the safety of ATG-101. It is the responsibility of the investigator to record and document all AEs (occurring from the first dose of study treatment on C1D1) throughout the study. Clinically significant symptoms and si...

    Recruiting

    Decorative Caduceus

    GCC19CART for Patients With Metastatic Colorectal Cancer

    Recruiting

    Contact me

    Share